Pharming Group N.V. Q2 2024 Financial Summary
Business Context and Reporting Period
This Form 6-K filing covers the preliminary (unaudited) financial results for the second quarter and first half of 2024, ended June 30, 2024. Pharming Group N.V. is a global biopharmaceutical company focused on rare diseases, primarily commercializing RUCONEST® (for acute HAE attacks) and Joenja® (leniolisib, for APDS). The company is listed on Euronext Amsterdam and Nasdaq.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | 1H 2024 | 1H 2023 |
|---|---|---|---|---|
| Total Revenue | $74.1 million | $54.9 million | $129.7 million | $97.4 million |
| Gross Profit | $66.1 million | $49.2 million | $113.3 million | $87.6 million |
| Operating Profit (Loss) | ($3.1 million) | $5.3 million | ($19.4 million) | ($8.4 million) |
| Net Profit (Loss) | ($1.2 million) | $1.3 million | ($13.7 million) | ($10.9 million) |
| Cash & Marketable Securities | $161.8 million | N/A | $161.8 million | $215.0 million (Year End) |
| Convertible Bonds (Liability) | $90.5 million | N/A | $90.5 million | $136.6 million (Year End) |
Revenue Breakdown (Q2 2024): RUCONEST® generated $63.0 million (96% from U.S. market). Joenja® generated $11.1 million (16% increase QoQ).
Material Changes vs. Prior Period
- Revenue Growth: Q2 2024 revenue increased 35% year-over-year (YoY), driven by a 23% increase in RUCONEST® revenue and a 192% increase in Joenja® revenue compared to Q2 2023.
- Operating Loss: The company reported an operating loss of $3.1 million in Q2 2024, compared to an operating profit of $5.3 million in Q2 2023. This shift is primarily due to the absence of a one-time $21.1 million gain from the sale of a Priority Review Voucher (PRV) in 2023 and increased operating expenses ($70.1 million vs. $65.8 million).
- Debt Refinancing: In April 2024, the company issued €100 million ($108 million) of new convertible bonds due 2029 to repurchase outstanding bonds due 2025. This resulted in a net cash outflow of approximately $30 million for the refinancing activity.
- Non-Operating Gains: A $5.1 million fair value gain was recorded in Q2 2024 due to the reclassification of the convertible bond conversion option from a derivative liability to equity.
Guidance, Outlook, and Risks
- 2024 Guidance: Management reaffirmed total revenue guidance of $280 million to $295 million, representing 14% to 20% growth. The company expects to remain on track despite quarterly fluctuations.
- Regulatory Updates:
- UK: Marketing Authorisation Application (MAA) for Joenja® is expected to receive a decision in Q4 2024.
- Europe (EEA): EMA CHMP affirmed positive clinical benefit but requested additional chemistry, manufacturing, and controls (CMC) data. Pharming has an extension until January 2026 to respond.
- Canada: Approval is no longer anticipated in 2024 following a Notice of Deficiency.
- Clinical Pipeline: A Phase II proof-of-concept trial for leniolisib in other Primary Immunodeficiencies (PIDs) is expected to initiate in Q3 2024.
- Liquidity: Cash and marketable securities declined to $161.8 million. Management states current cash and operating cash flows are sufficient to fund operations and investments for the next 12 months without material cash burn.
- Risks: Key risks include regulatory delays in Europe and Canada, the success of patient finding and VUS (Variant of Uncertain Significance) reclassification efforts, and the ability to execute the Phase II trial for new indications.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of Joenja® patient enrollment and adherence rates to ensure the 192% YoY growth is sustainable beyond the initial launch phase.
- Regulatory Timelines: Monitor the timeline for the European CMC response (deadline Jan 2026) and the UK MHRA decision (expected Q4 2024) as these impact future revenue streams.
- Debt Structure: Review the terms of the new 2029 convertible bonds, specifically the conversion price premium (37.5%) and potential dilution impact.
- Operating Expenses: Assess the trend in operating expenses, which increased to $134.0 million in 1H 2024, to ensure they align with revenue growth and do not widen the operating loss significantly.
- VUS Reclassification: Track the progress of the high-throughput screening study for VUS resolution, as this is critical for expanding the addressable patient population for Joenja®.